CompletedNCT06359899

A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD

This study evaluated the safety and effectiveness of AK0901 capsule for people with ADHD.

Medication studyAges 6–12China

The study in practice

Understand this study

This study evaluated the safety and effectiveness of AK0901 capsule for people with ADHD.

Listed age limits: 6 years to 12 years.

Listed locations: Beijing and 1 more locationSee all locations and recruitment
Study phase: Phase 3

Study clarity

Study start dateStarted: May 28, 2024

Recruitment status: Completed
Enrollment listed in the registry: 55
Sponsor: Shanghai Ark Biopharmaceutical Co., Ltd.
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: China
Age range: From 6 Years to 12 Years
Official registry ID: NCT06359899
Official title: Show the full official title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Investigate the Efficacy, Safety and Tolerability of Oral Administered AK0901 Capsules in Children Aged 6-12 Years Old With Attention Deficit Hyperactivity Disorder

Completed

Beijing

FAQ

What did researchers investigate?

This study evaluated the safety and effectiveness of AK0901 capsule for people with ADHD.

Who is behind this study?

The study sponsor is Shanghai Ark Biopharmaceutical Co., Ltd.

Did this study involve medication?

Yes. The study involved medication, including AK0901 capsule and Placebo.

Who was this study for?

Listed age limits: 6 years to 12 years.

Explore other studies

Explore HopeStage studies by mental health topic and refine the results to suit your situation.